CD16A-F Carriers Appear to Benefit Most From Margetuximab and Chemo
Margetuximab plus chemotherapy continues to improve outcomes in patients with HER2-positive metastatic breast cancer, particularly among CD16A-F carriers.
SABCS 2019
APHINITY Update: Pertuzumab Found to Lower Risk of Relapse in the Long Term, but Survival Benefit Is Unclear
Patients at high risk of recurrence had an invasive disease-free survival benefit from pertuzumab in the long term, but the survival benefit is unclear.
Endocrine Therapy With Palbociclib: No PFS Advantage in Metastatic Breast Cancer
Endocrine therapy with palbociclib did not offer a progression-free survival advantage over capecitabine in patients with metastatic breast cancer.
Prediction Models May Help Forecast Response, Adverse Events With CDKI Therapy
Prediction models helped forecast how patients with metastatic breast cancer would respond to CDKI therapy and the adverse events they may develop.
Breast Cancer Risk Identified for Predisposition Genes in General Population
In the general population, BRCA1, BRCA2, PALB2, and ATM mutations were linked to a significant increased risk of breast cancer.
Adding Tucatinib Led to Survival Gain in Metastatic Breast Cancer
Adding tucatinib to capecitabine and trastuzumab improved survival for patients with metastatic HER2-positive breast cancer, including those with brain metastases.
The 2019 San Antonio Breast Cancer Symposium: What to Expect
Talks from the meeting will offer insights on the prevention and diagnosis of disease, and will also compare novel therapeutic interventions with older standards of care.
- Loading...
Loading...
Loading... 
Loading...